Top Page
Adherium Ltd.
(Sydney:ADR)
Adherium Ltd. (ADR) vs. iShares MSCI Australia ETF (EWA)
Adherium Ltd. Business Overview & Revenue Model
Adherium Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 817.24K | 817.24K | 840.98K | 3.19M | 529.00K | 401.00K |
| Gross Profit | 111.37K | 111.37K | 267.70K | 1.69M | -690.00K | -789.00K |
| EBITDA | -12.44M | -12.44M | -11.56M | -11.50M | -12.65M | -13.03M |
| Net Income | -12.68M | -12.68M | -10.22M | -9.86M | -10.04M | -15.04M |
Balance Sheet | ||||||
| Total Assets | 3.52M | 3.52M | 9.89M | 12.68M | 8.53M | 17.04M |
| Cash, Cash Equivalents and Short-Term Investments | 43.26K | 43.26K | 6.20M | 9.08M | 5.28M | 15.18M |
| Total Debt | 3.12M | 3.12M | 93.20K | 44.00K | 85.00K | 0.00 |
| Total Liabilities | 8.28M | 8.28M | 3.41M | 3.47M | 3.00M | 3.00M |
| Stockholders Equity | -4.76M | -4.76M | 6.48M | 9.21M | 5.54M | 14.04M |
Cash Flow | ||||||
| Free Cash Flow | -10.03M | -10.03M | -10.61M | -9.32M | -9.89M | -11.30M |
| Operating Cash Flow | -9.98M | -9.98M | -10.61M | -9.28M | -9.61M | -11.27M |
| Investing Cash Flow | -48.19K | -48.19K | -37.00 | -41.00K | -279.00K | -29.00K |
| Financing Cash Flow | 3.87M | 3.87M | 7.73M | 13.07M | 0.00 | 21.90M |
Adherium Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | €36.47M | -6.73 | -513.22% | ― | -34.06% | 75.47% | |
45 Neutral | AU$13.43M | -1.63 | -103.74% | ― | 14.84% | 39.64% | |
43 Neutral | AU$21.87M | -3.51 | -58.27% | ― | -7.20% | 28.70% | |
39 Underperform | AU$3.12M | -0.91 | -218.52% | ― | -30.80% | -38.95% | |
38 Underperform | AU$5.67M | -4.19 | ― | ― | ― | -55.00% | |
37 Underperform | AU$8.67M | -0.64 | -1476.79% | ― | -2.82% | 32.47% |
Adherium Ltd. Corporate Events
Adherium Limited announced a correction to a previous notification regarding the number of issued options due to an administrative error. This update, which affects the company’s unquoted equity securities, highlights the importance of accurate reporting and may influence stakeholders’ perception of the company’s operational diligence.
Adherium Limited has announced an Early Exercise Incentive Offer for its optionholders, allowing them to receive a bonus option for each existing option exercised by November 15, 2025. This initiative aims to streamline the exercise process in line with the company’s cash-flow management and ensure compliance with voting power thresholds, potentially impacting the company’s financial operations and stakeholder interests.
Adherium Ltd. has released a presentation outlining its current position and future prospects in the respiratory care sector. The company acknowledges the inherent risks and uncertainties in its operations, including product development delays and regulatory hurdles, which could impact its market penetration and financial performance. Stakeholders are advised to consider these factors when evaluating the company’s potential growth and success.
Adherium Limited announced an investor webinar to be hosted by CEO Dawn Bitz, aimed at updating stakeholders on the company’s recent activities and future outlook. The webinar signifies Adherium’s commitment to transparency and engagement with investors, potentially impacting its market positioning and stakeholder relations positively.
Adherium Limited’s Hailie Smartinhaler system is revolutionizing the management of chronic respiratory conditions by enhancing patient adherence and self-management, ultimately reducing hospital admissions and healthcare costs. The company is actively expanding its sales in the US and other markets by forming strategic partnerships with major healthcare entities, positioning itself as a leader in digital health solutions for respiratory care.
Adherium Limited announced the issuance of 8,351 fully paid ordinary shares without disclosure to investors under the Corporations Act 2001. The company has complied with relevant legal provisions and confirmed there is no excluded information requiring disclosure, indicating a smooth operational process and adherence to regulatory standards.
Adherium Limited announced the late lodgement of two Appendices 3Y related to changes in notifiable interests, which were not due to on-market trades. The company assured stakeholders that this administrative oversight was an isolated incident and that their current compliance arrangements with ASX Listing Rules are adequate, requiring no additional steps.
Adherium Limited announced a change in the director’s interest, specifically regarding George Baran’s holdings. The changes involve the acquisition and disposal of various securities, including fully paid ordinary shares, unlisted options, and convertible notes. This adjustment in holdings could impact the company’s financial structure and stakeholder interests, reflecting strategic decisions in managing director-level investments.
Adherium Limited announced a change in the interests of its director, Louis Panaccio, involving the acquisition and disposal of securities. The change includes the lapse of certain unlisted options and the acquisition of fully paid ordinary shares and new unlisted options. This adjustment in securities reflects ongoing strategic financial maneuvers by the company to align its resources and strengthen its market position.
Adherium Ltd. has announced the issuance of new unquoted equity securities, specifically options exercisable at $0.005, set to expire on November 15, 2026. This move could potentially impact the company’s financial strategy and market positioning by expanding its equity base and offering new investment opportunities.
Adherium Limited reported a loss of $12.68 million for the year ended June 30, 2025, an increase from the previous year’s loss. The company’s revenue slightly decreased to $817,237, while research and development expenses dropped as it shifted focus from clinical trials to commercialization. Sales and marketing costs rose significantly due to expansion in the US market. Despite ending the year with reduced cash reserves, Adherium successfully raised $4.492 million through an entitlement offer, exceeding its initial target.
Adherium Ltd. has announced the issuance of 66,208,082 unquoted securities, set to expire on July 31, 2026, with an exercise price of $0.005. This strategic move, part of a previously announced transaction, is expected to enhance the company’s capital structure and support its ongoing initiatives in digital health technology, potentially impacting its market positioning positively.
Adherium Limited has issued 66,208,082 fully paid ordinary shares without disclosure to investors under the Corporations Act 2001. The company confirms compliance with relevant provisions of the Act and states there is no excluded information required to be disclosed. This announcement reflects Adherium’s ongoing commitment to maintaining transparency and regulatory compliance, which may impact its market positioning and stakeholder confidence.
Adherium Ltd. announced the quotation of 66,208,082 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of a previously announced transaction. This move is expected to enhance the company’s financial flexibility and potentially strengthen its market position within the digital health sector, offering potential benefits to stakeholders.
Adherium Limited announced a proposed issue of securities, including 70,208,082 ordinary fully paid shares and 70,208,082 options expiring on July 31, 2026, with an exercise price of $0.005. This strategic move is aimed at raising capital, potentially strengthening the company’s financial position and supporting its growth initiatives in the digital health sector.
Adherium Limited has successfully secured A$0.35 million through an institutional placement to bolster its financial flexibility and working capital. This capital raise, alongside existing cash reserves and proceeds from a recent entitlement offer, positions Adherium to pursue organic growth opportunities and strengthens its balance sheet, enhancing its ability to execute strategic objectives.
Adherium Limited announced a delay in lodging the Appendix 3H with the ASX due to an administrative oversight, which the company views as an isolated incident. Despite this, Adherium maintains confidence in its compliance practices with ASX Listing Rules, suggesting minimal impact on its operations or stakeholder relations.
Adherium Limited announced the cessation of 418,539,981 securities due to the expiry of options without exercise or conversion as of June 30, 2025. This development may impact the company’s capital structure and could influence investor perceptions regarding its financial strategy and market positioning.